{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "IRON",
  "name": "Disc Medicine, Inc.",
  "url": "https://frontierpicks.com/dossiers/IRON/",
  "json_url": "https://frontierpicks.com/dossiers/IRON.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Disc Medicine's bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection, so the shares are modestly favoured to beat the S&P 500. The year-end 2026 NDA resubmission and the December ASH data decide it.",
  "invalidation_trigger": "A daily close below $78.47, the 2026-11-05 close on the day of the third-quarter report and the at-the-market filing, which would erase the post-report gains; or no bitopertin NDA resubmission announced by 2026-12-31.",
  "catalyst_date": "2026-12-12",
  "portfolio": null,
  "pick": null,
  "themes": [
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Disc Medicine has no approved product; its revenue and valuation depend on FDA approval of bitopertin, expected by mid-2027 per company guidance.",
    "An at-the-market sales agreement with TD Cowen, filed 2026-11-05, allows the company to sell up to $189.93 million of common stock over time.",
    "News about Ironveld plc, a UK-listed miner, sometimes appears under the IRON ticker and is unrelated to Disc Medicine."
  ],
  "source_links": [
    {
      "title": "Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)",
      "url": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-success-all-primary-and-secondary",
      "date": null
    },
    {
      "title": "Disc Medicine Reports Strong Q3 2026 Results",
      "url": "https://www.biopharmawatch.com/news/IRON/disc-medicine-q3-2026-financial-results-update",
      "date": null
    },
    {
      "title": "Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update",
      "url": "https://www.globenewswire.com/news-release/2026/11/05/3396436/0/en/disc-medicine-reports-third-quarter-2026-financial-results-and-provides-business-update.html",
      "date": "2026-11-05"
    },
    {
      "title": "hcplive.com",
      "url": "https://www.hcplive.com/view/fda-issues-complete-response-letter-bitopertin-erythropoietic-protoporphyria",
      "date": "2026-02-13"
    },
    {
      "title": "pharmexec.com",
      "url": "https://www.pharmexec.com/view/fda-crl-disc-medicine-eythropoietic-protoporphyria-treatment-bitopertin",
      "date": "2026-02-16"
    },
    {
      "title": "Disc Medicine's Bitopertin Meets All Phase 3 Goals; FDA Resubmission Planned",
      "url": "https://www.rttnews.com/3700154/disc-medicine-s-bitopertin-meets-all-phase-3-goals-fda-resubmission-planned.aspx",
      "date": null
    },
    {
      "title": "Explore the Premier Event in Classical and Malignant Hematology",
      "url": "https://www.hematology.org/meetings/annual-meeting",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Phase 3 APOLLO (183 patients) met all endpoints: PPIX down 41.4% vs placebo (p<0.0001), +12.2 hours monthly time in light without pain (p=0.0010).",
      "source": "Disc Medicine press release, 2026-10-19",
      "as_of": "2026-10-19"
    },
    {
      "claim": "FDA complete response letter for bitopertin in EPP said the PPIX surrogate was not shown to predict clinical benefit and asked for data from another trial.",
      "source": "HCPLive / PharmExec coverage of the CRL, 2026-02-13 to 2026-02-16",
      "as_of": "2026-02-13"
    },
    {
      "claim": "Q3 2026 net loss $59.5M ($1.53 per share) vs $62.3M a year earlier; per-share loss beat the $1.76 consensus estimate.",
      "source": "Q3 2026 results release and 10-Q, 2026-11-05",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Cash, equivalents and marketable securities $682.8M at 2026-09-30; company guides runway into 2030 including October offering proceeds.",
      "source": "Q3 2026 results release, 2026-11-05",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Upsized public offering of 6,000,000 shares priced at $75.00, $450M gross proceeds.",
      "source": "Disc Medicine offering pricing release, 2026-10-21",
      "as_of": "2026-10-21"
    },
    {
      "claim": "At-the-market sales agreement with TD Cowen for up to $189.93M of common stock.",
      "source": "Disc Medicine filing reported 2026-11-05",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Guggenheim initiated coverage at Buy with a $132 target; HC Wainwright raised its target to $127 on 2026-11-06.",
      "source": "Benzinga analyst reports, 2026-11-06 and 2026-11-09",
      "as_of": "2026-11-09"
    },
    {
      "claim": "Director Kevin Bitterman sold 41,825 shares at an average $80.13 on 2026-10-19 to 2026-10-21 under a Rule 10b5-1 plan.",
      "source": "SEC Form 4 filed 2026-10-21",
      "as_of": "2026-10-21"
    }
  ],
  "view_changes": [],
  "body_markdown": "## Current Thesis\n\nDisc Medicine's lead drug, bitopertin, passed its Phase 3 APOLLO trial on 2026-10-19. That result answers the reason the Food and Drug Administration (FDA) rejected the drug in February, which makes the shares modestly more likely than not to beat the S&P 500 over the next three months. The case depends on the company resubmitting the new drug application (NDA) by the end of 2026, as it has guided, and on its other blood-disorder programs at the American Society of Hematology (ASH) meeting on 2026-12-12 to 2026-12-15.\n\nThe FDA issued a complete response letter (CRL) on 2026-02-13. Press coverage of the letter reported that the agency accepted that bitopertin lowers protoporphyrin IX (PPIX), the toxic metabolite that drives erythropoietic protoporphyria (EPP), a rare disease that makes sunlight painful. The agency did not accept that the drop predicts clinical benefit, and it asked for a further trial. APOLLO measured that benefit directly. It enrolled 183 patients and cut PPIX by 41.4% against placebo (p<0.0001). It added 12.2 hours a month of time in light without pain (p=0.0010), and every secondary endpoint was met, according to the company's 2026-10-19 release.\n\nThe company expects an FDA decision by mid-2027. The rating is MEDIUM because the main question from the February letter now has a direct answer, while a funding overhang and a rally that is already large keep the probability well short of high. At the $87.08 close on 2026-11-11, the shares sit 12.5% below the $99.50 intraday high of 2025-12-08, set before the rejection. On that gap, the price already credits most of the approval odds the shares lost in February.\n\n## Bull Case\n\n- **APOLLO answers the FDA's stated objection.** The CRL asked for proof that the PPIX drop means real benefit for patients. APOLLO showed a 12.2-hour monthly gain in pain-free light exposure against placebo (company release, 2026-10-19), and coverage of the letter reported no manufacturing issues were raised.\n- **Funding runs into 2030.** Cash, equivalents and marketable securities were $682.8 million on 2026-09-30, before the October offering. The company says its cash plus the offering's proceeds fund operations into 2030 (third-quarter report, 2026-11-05).\n- **Two more programs report at ASH.** Updated selcodebart data in anemia of myelofibrosis, along with polycythemia vera and sickle cell data for DISC-3405, will be presented at ASH from 2026-12-12 (company release, 2026-11-04). The company also expects FDA feedback on a pivotal selcodebart plan by the end of 2026.\n- **Analyst targets moved up after the report.** Guggenheim started coverage with a Buy rating and a $132 target on 2026-11-09. HC Wainwright raised its target to $127 on 2026-11-06.\n- **Losses narrowed.** The third-quarter net loss was $59.5 million, or $1.53 a share, against $62.3 million a year earlier. The loss per share beat the $1.76 consensus estimate (2026-11-05).\n\n## Bear Case\n\n- **New shares keep coming to market.** The company priced 6,000,000 shares at $75.00 on 2026-10-21 for $450 million gross. On 2026-11-05 it filed an at-the-market sales agreement with TD Cowen for up to $189.93 million more, which can add supply into any rally.\n- **Directors and officers have sold steadily.** SEC Form 4 filings show director Kevin Bitterman sold 41,825 shares at an average of $80.13 between 2026-10-19 and 2026-10-21 under a Rule 10b5-1 plan. Chief Executive Officer John Quisel sold 33,000 shares at an average of $79.15 on 2026-08-17 under such a plan.\n- **Tolerability could shape the label.** Dizziness was the most common adverse event in APOLLO, reported in 50% of patients, mostly mild or moderate, according to the third-quarter update of 2026-11-05.\n- **The approval is still months away.** The company guides to an FDA decision by mid-2027, past the three-month window. A gain in the shares before then depends on filing milestones and pipeline data.\n\n## Setup & Price Structure\n\nThe shares closed at $87.08 on 2026-11-11, their third straight higher close after $78.91 on 2026-11-06. As of 2026-11-11, the 50-day moving average is $71.52 and the 200-day moving average is $70.93. The last close sits well above both.\n\nThe 52-week closing low is $55.74, set on 2026-10-14, five sessions before the APOLLO results. The 52-week intraday high is $99.50, set on 2025-12-08. The 3-month change is 8.8%, measured from the $80.01 close on 2026-08-13. The $75.00 October offering price is the level at which institutions took the largest block of new stock.\n\nThe $99.50 high marks where the market priced bitopertin before the rejection. A move back toward it would mean the market treats the resubmission as close to a full reversal of the February letter.\n\n## Catalyst Calendar\n\n- **2026-12-12:** 68th ASH Annual Meeting (2026-12-12 to 2026-12-15): selcodebart RALLY-MF update, DISC-3405 polycythemia vera and sickle cell data. Shows whether the pipeline behind bitopertin holds up, which matters for value beyond a single EPP approval.\n- **~2026-12-31 (est.):** Bitopertin NDA resubmission to the FDA, guided for the end of 2026. Filing on time keeps the mid-2027 decision on track; the FDA's acknowledgment and goal date then set the review clock.\n- **~2026-12-31 (est.):** Selcodebart End-of-Phase 2 FDA feedback and pivotal plan for anemia of myelofibrosis. Sets whether a second program moves into a registration trial in 2027.\n- **~2027-06-30 (est.):** Expected FDA decision on resubmitted bitopertin NDA (mid-2027 per company). Approval would make Disc Medicine a commercial company; a second rejection would remove most of the case.\n\n## What Would Change Our Mind\n\nA daily close below $78.47, the 2026-11-05 close on the day of the third-quarter report and the at-the-market filing, which would erase the post-report gains; or no bitopertin NDA resubmission announced by 2026-12-31.\n\nThe risks this note tracks, each with what would confirm it:\n\n- The bitopertin resubmission slips past the guided end-2026 timing. Confirmed by: No company announcement of the NDA resubmission by 2026-12-31.\n- The FDA sets a review goal later than mid-2027 or raises new questions on the resubmitted application. Confirmed by: A company disclosure of an FDA action date after 2027-06-30 or of an advisory committee meeting.\n- Share sales under the TD Cowen at-the-market program dilute holders and cap rallies. Confirmed by: ATM proceeds or a higher share count reported in the 2026 10-K.\n- Dizziness, reported in 50% of APOLLO patients, leads to a restrictive label or weak uptake. Confirmed by: FDA labeling discussions or full APOLLO data showing discontinuations tied to dizziness.\n- Pipeline data at ASH disappoint and the market reprices the non-bitopertin programs. Confirmed by: Updated RALLY-MF or RESTORE-PV data at ASH from 2026-12-12 showing weaker responses than earlier cohorts.\n\n## Correlation Notes\n\nDisc Medicine's shares trade mainly on the company's own regulatory and trial dates. The 2026-10-19 APOLLO result and the 2026-02-13 rejection drove the largest moves of the past year. Between those dates, the shares tend to track small- and mid-cap biotech sentiment. Companies in the same rare-disease group (Viridian Therapeutics, Xeris Biopharma, Septerna, Delcath) report on unrelated assets, so their own results carry little information about bitopertin's review.\n\nHeadlines tagged with the IRON ticker about Ironveld plc, a UK-listed miner, appeared in late October and early November 2026. They concern a different company.",
  "first_seen": "2026-11-11",
  "last_analyzed": "2026-11-11T23:25:11+00:00",
  "last_synthesized": "2026-11-11",
  "date_modified": "2026-11-11",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}